Li Y G, Wu J F, Li X
Drug Discov Ther. 2009 Feb;3(1):1.
The successive appearance of strains of epizootic avian influenza A virus with the subtype H5N1 in China has attracted considerable concern from the public and Chinese authorities. According to the latest WHO estimates as of February 2, 2009, the number of H5N1 virus deaths in China totaled 25, second only to Indonesia and Viet Nam (http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_02_02/en/index.html). The H5N1 virus is highly contagious among birds and is fatal when transmitted to humans, though the means by which this occurs is still unknown. Owing to the possible variation of the H5N1 prototype virus, together with the fact that it has the propensity to exchange genes with influenza viruses from other species, humans have no natural immunity to the virus. Despite years of efforts, the exact pathogenesis of H5N1 transmission to humans is still not completely clear, nor is potential human-tohuman transmission as could lead to an epidemic or even worldwide pandemic (Enserink M. Science. 2009; 323:324). Unfortunately, current antiviral treatment and therapeutic measures cannot effectively overcome this virulent virus that causes highly pathogenic avian influenza (HPAI). Researchers from around the world are working to study the virology of influenza viruses, including their methods of infiltration, replication, and transcription, to elucidate the mechanisms of unremitting viral infection in terms of aspects such as the virus, host, and environment. These researchers are also working to identify potential molecular targets related to H5N1 for anti-influenza drug intervention. A recent H5N1-related study from China provides encouraging information. According to the People's Daily (Renmin Ribao), a newspaper out of Beijing, professor Liu Yingfang, academician Rao Zihe, and fellow researchers from more than 6 research centers, including the Institute of Biophysics Chinese Academy of Sciences, Nankai University, and Tsinghua University, have achieved exciting results in providing a detailed understanding of the mechanisms of action of the RNA polymerase PA subunit, the "heart" of the avian influenza virus, at the atomic level. They hope to provide clues to potential avian influenza therapy targets and a new platform for new drug discovery (http://202.123.110.5/jrzg/2009-02/06/content_1222973.htm, available as of February 6, 2009). According to Liu et al., influenza viruses are enveloped, negatively stranded RNA viruses with a segmented genome (consisting of 8 RNA segments) that can encode 11 kinds of viral proteins. Among these proteins, the complex of influenza polymerase, consisting of PB1, PB2, and PA subunits, is regarded to be what gives life to influenza viruses because of its essential catalytic role in viral RNA replication and mRNA transcription in the nucleus of infected cells. Notwithstanding earlier virology studies on the influenza virus that elucidated the functions of PB1 and PB2, the exact function of PA is still not completely clear. The group resolved the crystal structure of the carboxyl-terminus of PA in complex with the aminoterminus of PB1 peptides for the first time. This structure mode provides details for the interactions of PA and PB1, as well as the binding sites of PA and RNA. Results of the research, entitled the "Crystal structure of the polymerase PA(c)-CPB1(N) complex from an avian influenza H5N1 virus," were published in the August 28th issue of the respected international scientific journal Nature (He X, Zhou J, Bartlam M, et al. Nature. 2008; 454:1123-1126). Further efforts by the group served to indicate the fine three-dimensional structure of the N-terminal of PA protein. They revealed that the PA subunit holds an endonuclease active site and that it, rather than the PB1 subunit as was previously, plays a critical role in the endonuclease activity of influenza virus polymerase. In addition, PA's characteristics of being highly conserved and having little mutations make it an attractive target for anti-influenza therapeutics. Specifically, endonuclease can block the mRNA of host cells cached by the complex of polymerase, resulting in mRNA transcription. Results of the group's most recent research have been published in a recent February 4th issue of Nature (Yuan P, Bartlam M, Lou Z, et al. Nature. 2009; Epub ahead of print).
中国相继出现H5N1亚型高致病性禽流感病毒毒株,引起了公众和中国政府的高度关注。根据世界卫生组织(WHO)截至2009年2月2日的最新估计,中国H5N1病毒死亡人数总计25人,仅次于印度尼西亚和越南(http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_02_02/en/index.html)。H5N1病毒在禽类中具有高度传染性,传播给人类时具有致命性,但其传播途径尚不清楚。由于H5N1原型病毒可能发生变异,且有与其他物种的流感病毒交换基因的倾向,人类对该病毒没有天然免疫力。尽管经过多年努力,H5N1病毒传播给人类的确切发病机制仍不完全清楚,其潜在的人际传播导致疫情甚至全球大流行的可能性也不清楚(恩瑟林克M.《科学》.2009年;323:324)。不幸的是,目前的抗病毒治疗和治疗措施无法有效战胜这种导致高致病性禽流感(HPAI)的烈性病毒。世界各地的研究人员正在努力研究流感病毒的病毒学,包括其渗透、复制和转录方法,以从病毒、宿主和环境等方面阐明病毒持续感染的机制。这些研究人员还在努力确定与H5N1相关的潜在分子靶点,用于抗流感药物干预。中国最近一项与H5N1相关的研究提供了令人鼓舞的信息。据北京的报纸《人民日报》报道,中国科学院生物物理研究所、南开大学、清华大学等6个以上研究中心的刘迎芳教授、饶子和院士及其他研究人员,在原子水平上详细了解禽流感病毒“核心”RNA聚合酶PA亚基的作用机制方面取得了令人振奋的成果。他们希望为潜在的禽流感治疗靶点提供线索,并为新药研发提供新平台(http://202.123.110.5/jrzg/2009-02/06/content_1222973.htm,截至2009年2月6日可获取)。根据刘等人的研究,流感病毒是包膜的负链RNA病毒,基因组呈节段状(由8个RNA节段组成),可编码11种病毒蛋白。在这些蛋白中,由PB1、PB2和PA亚基组成的流感病毒聚合酶复合体,因其在受感染细胞细胞核中的病毒RNA复制和mRNA转录中起关键催化作用,而被认为是赋予流感病毒生命的物质。尽管早期对流感病毒的病毒学研究阐明了PB1和PB2的功能,但PA的确切功能仍不完全清楚。该团队首次解析了PA羧基末端与PB1肽氨基末端复合物的晶体结构。这种结构模式为PA与PB1的相互作用以及PA与RNA的结合位点提供了详细信息。这项名为“禽流感H5N1病毒聚合酶PA(c)-CPB1(N)复合物的晶体结构”的研究结果发表在8月28日备受尊敬的国际科学期刊《自然》上(何X、周J、巴特尔姆M等.《自然》.2008年;454:1123 - 1126)。该团队的进一步研究揭示了PA蛋白N末端的精细三维结构。他们发现PA亚基具有一个核酸内切酶活性位点,并且在流感病毒聚合酶的核酸内切酶活性中,它而非PB1亚基起着关键作用。此外,PA高度保守且突变较少的特性使其成为抗流感治疗的有吸引力靶点。具体而言,核酸内切酶可阻断聚合酶复合体截留的宿主细胞mRNA,从而导致mRNA转录。该团队最新研究结果已发表在最近2月4日的《自然》杂志上(袁P、巴特尔姆M、娄Z等.《自然》.2009年;网络版提前发表)。